CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity

Key Points

• Enhanced antibacterial activity was observed with LL37, targeting Salmonella effectively and improving treatment outcomes.
• The study found that CRISPR/Cas9-engineered phages led to a 50% increase in antibacterial efficacy against Salmonella strains.
• Analysis using phage display techniques demonstrated effective delivery of the antimicrobial peptide LL37 to bacterial cells.
• Potential for novel phage therapy approaches is highlighted, paving the way for new treatments against antibiotic-resistant bacteria.